Abstract |
We generated several attenuated recombinant influenza A vectors expressing the Mycobacterium tuberculosis early secretory antigenic target (ESAT-6) protein. The ESAT-6 protein was recently identified as one of the most promising protective antigens for cell-mediated immunity. The obtained vectors appeared to be capable of inducing ESAT-6 specific Th1 immune response in mice after intranasal immunization. We found that double immunization with two influenza vectors of different subtypes provided a significant level of protection in mice, when applied as prophylactic vaccine, as well as substantial therapeutic effect in mice with pre-established tuberculosis infection. Moreover, we found a strong synergistic effect when vaccination with Flu/ESAT-6 vectors was combined with isoniazid treatment, resulting in a dramatic reduction of bacterial load in the lungs of infected mice.
|
Authors | M A Stukova, S Sereinig, N V Zabolotnyh, B Ferko, C Kittel, J Romanova, T I Vinogradova, H Katinger, O I Kiselev, A Egorov |
Journal | Tuberculosis (Edinburgh, Scotland)
(Tuberculosis (Edinb))
2006 May-Jul
Vol. 86
Issue 3-4
Pg. 236-46
ISSN: 1472-9792 [Print] Scotland |
PMID | 16677861
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, Bacterial
- Antitubercular Agents
- Bacterial Proteins
- ESAT-6 protein, Mycobacterium tuberculosis
- Tuberculosis Vaccines
- Isoniazid
|
Topics |
- Administration, Intranasal
- Animals
- Antigens, Bacterial
(genetics, immunology, therapeutic use)
- Antitubercular Agents
(therapeutic use)
- Bacterial Proteins
(genetics, immunology, therapeutic use)
- Combined Modality Therapy
- Genetic Vectors
(administration & dosage)
- Immunity, Cellular
- Immunization
(methods)
- Influenza A virus
(genetics)
- Isoniazid
(therapeutic use)
- Mice
- Mice, Inbred C57BL
- Mycobacterium tuberculosis
(immunology)
- Th1 Cells
(immunology)
- Tuberculosis
(immunology, prevention & control, therapy)
- Tuberculosis Vaccines
(immunology, therapeutic use)
|